Why the study?
Does propranolol reduce elevated platelet function in men with untreated mild hypertension?
Does propranolol reduce elevated platelet function in men with untreated mild hypertension?
The normalization of elevated platelet function observed during anti-hypertensive therapy may be due to patient adaptation to blood sampling rather than a pharmacological effect.
Normalization of BTG during placebo indicates sampling adaptation; challenges propranolol effect on platelets and should not yet change practice.
Blood platelet function was evaluated in 10 men, all 50 years old, with untreated, mild hypertension. Each patient was examined four times: At the beginning of the study, after 5 weeks on placebo treatment, after the following 5 weeks on propranolol 160 mg daily, and finally after a second period of 5 weeks on placebo. At baseline the plasma level of the platelet release product beta-thromboglobulin (BTG) was 41.6 (30.5-57.0) micrograms/l (median and 95% confidence interval). During the first placebo period BTG was normalized to 21.0 (14.1-25.9) micrograms/l. While systolic blood pressure and heart rate fell during beta-adrenergic receptor blockade, BTG remained unchanged throughout the rest of the observation periods. Platelet size increased significantly during treatment with beta-blocker. The present study indicates that the normalization of elevated platelet function which previously has been reported to occur during anti-hypertensive drug therapy, may be explained by patient adaptation to the blood sampling procedure.
No takes yet. Share an insight, caveat, or question.
Lande et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: